| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/AJO.12399 |
| P698 | PubMed publication ID | 26412014 |
| P50 | author | Joanne Said | Q42836866 |
| Michael Paech | Q59161536 | ||
| P2093 | author name string | Lawrence P McMahon | |
| Robyn A North | |||
| Karin Lust | |||
| Sandra A Lowe | |||
| Lucy Bowyer | |||
| Mark Morton | |||
| P2860 | cites work | The relationship between calcium intake and pregnancy-induced hypertension: up-to-date evidence | Q39639254 |
| The HELLP syndrome: clinical issues and management. A Review | Q21261342 | ||
| Drugs for treatment of very high blood pressure during pregnancy | Q24200974 | ||
| Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome | Q24241127 | ||
| VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632982 | ||
| Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis | Q26825271 | ||
| Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia | Q28192233 | ||
| Aspirin for pre-eclampsia: compelling data on benefit and risk | Q28211043 | ||
| Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data | Q28211057 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial | Q30512857 | ||
| The effects of an increase of central blood volume before spinal anesthesia for cesarean delivery: a qualitative systematic review | Q30660798 | ||
| Relationship between periodontitis and pre-eclampsia: a meta-analysis | Q31131325 | ||
| Proteinuria and its assessment in normal and hypertensive pregnancy | Q33205586 | ||
| Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review | Q33327641 | ||
| Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity | Q33329194 | ||
| The prevalence and clinical significance of nocturnal hypertension in pregnancy | Q33338627 | ||
| Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes | Q33377706 | ||
| Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. | Q33378261 | ||
| Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group | Q33381983 | ||
| Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial | Q33382169 | ||
| Vitamins C and E to prevent complications of pregnancy-associated hypertension | Q33389072 | ||
| Effects of calcium supplementation on uteroplacental and fetoplacental blood flow in low-calcium-intake mothers: a randomized controlled trial | Q33498238 | ||
| Postpartum recovery after severe pre-eclampsia and HELLP-syndrome | Q33499076 | ||
| Assessment of changes in coagulation in parturients with preeclampsia using thromboelastography | Q33505162 | ||
| The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies | Q33610047 | ||
| Fetal biophysical profile | Q33788102 | ||
| The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. | Q33863487 | ||
| Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population? | Q33923716 | ||
| Pregnancy outcome in women presenting with pre-eclampsia at less than 25 weeks gestation | Q40291027 | ||
| Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis | Q40528289 | ||
| Treatment of hypertension in pregnant women | Q41002739 | ||
| Epidural lidocaine-bicarbonate-adrenaline vs levobupivacaine for emergency Caesarean section: a randomised controlled trial | Q42004786 | ||
| Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies | Q42058587 | ||
| Resolution of hypertension and proteinuria after preeclampsia | Q43419193 | ||
| Postpartum management of hypertension. | Q43994007 | ||
| Effect of concentration and biochemical assay on the accuracy of urine dipsticks in hypertensive pregnancies | Q44014214 | ||
| Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry | Q44016206 | ||
| Folic acid supplementation in early second trimester and the risk of preeclampsia | Q44054579 | ||
| Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain & Ireland The Obstetric Anaesthetists' Association Regional Anaesthesia UK. | Q44128043 | ||
| Capillary permeability and extracellular fluid volumes in pregnancy-induced hypertension | Q44481625 | ||
| Prospective, randomized trial comparing general with spinal anesthesia for cesarean delivery in preeclamptic patients with a nonreassuring fetal heart trace | Q44576588 | ||
| A population-based study of venous thrombosis in pregnancy in Scotland 1980-2005. | Q44686703 | ||
| Editorial I: Spinal anaesthesia for Caesarean delivery: keep the pressure up and don't spare the vasoconstrictors | Q44795365 | ||
| Maternal and perinatal outcome of preeclampsia with an onset before 24 weeks' gestation. Audit in a tertiary referral center | Q44803457 | ||
| Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study | Q45747422 | ||
| Long-term risk of sustained hypertension in white-coat or masked hypertension. | Q45947352 | ||
| Masked hypertension: different blood pressure measurement methodology and risk factors in a working population. | Q46011159 | ||
| World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. | Q46016413 | ||
| Impact of the HYPITAT trial on doctors' behaviour and prevalence of eclampsia in the Netherlands. | Q46164521 | ||
| Expectant management of early onset, severe pre-eclampsia: perinatal outcome | Q46185721 | ||
| A prospective randomized study of automated versus mercury blood pressure recordings in hypertensive pregnancy (PRAM Study). | Q46328794 | ||
| Preeclamptic angina--a pathognomonic symptom of preeclampsia | Q46329026 | ||
| Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. | Q46333378 | ||
| Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study | Q46337233 | ||
| Instituting surveillance guidelines and adverse outcomes in preeclampsia | Q46338992 | ||
| Maternal deaths from anaesthesia. An extract from Why Mothers Die 2000-2002, the Confidential Enquiries into Maternal Deaths in the United Kingdom: Chapter 17: Trends in intensive care | Q46344837 | ||
| Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure | Q46345137 | ||
| Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial | Q46351253 | ||
| Expectant management of severe pre-eclampsia in the mid-trimester | Q46353224 | ||
| Neonatal outcome in severe preeclampsia at 24 to 36 weeks' gestation: does the HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome matter? | Q46357134 | ||
| High-dose dexamethasone in the treatment of HELLP syndrome | Q46376966 | ||
| Calcium supplementation during pregnancy for preventing hypertensive disorders is not associated with changes in platelet count, urate, and urinary protein: a randomized control trial | Q46433960 | ||
| Expectant management of early onset, severe pre-eclampsia: maternal outcome | Q46436845 | ||
| The natural history of white coat hypertension during pregnancy | Q46447073 | ||
| Spinal versus epidural anesthesia for cesarean delivery in severe preeclampsia: a prospective randomized, multicenter study | Q46663935 | ||
| Spinal anesthesia-induced hypotension: a risk comparison between patients with severe preeclampsia and healthy women undergoing preterm cesarean delivery | Q46663938 | ||
| Dexamethasone treatment does not improve the outcome of women with HELLP syndrome: a double-blind, placebo-controlled, randomized clinical trial | Q46783753 | ||
| Is there an ideal approach for rapid-sequence induction in hypertensive patients? | Q46975740 | ||
| Effect of atenolol on birth weight | Q47308672 | ||
| Inter-arm blood pressure differences in pregnant women. | Q47390453 | ||
| Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications | Q47396374 | ||
| Undiagnosed phaeochromocytoma mimicking severe preeclampsia in a pregnant woman at term | Q47580430 | ||
| What is the role of out-of-office BP measurement in hypertensive pregnancy? | Q47702963 | ||
| Risk factors for first venous thromboembolism around pregnancy: a population-based cohort study from the United Kingdom. | Q47828223 | ||
| Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies | Q47831716 | ||
| Optimal timing of delivery in pregnancies with pre-existing hypertension | Q47840776 | ||
| Increased frequency of genetic thrombophilia in women with complications of pregnancy | Q47868847 | ||
| Validation of the A&D UM-101 professional hybrid device for office blood pressure measurement according to the International Protocol | Q47973361 | ||
| Long-term visual functioning after eclampsia | Q48451806 | ||
| Impaired maternal cognitive functioning after pregnancies complicated by severe pre-eclampsia: a pilot case-control study | Q48503625 | ||
| A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial | Q48583641 | ||
| Failed intubation in obstetrics: a self-fulfilling prophecy? | Q48640931 | ||
| Maternal haemodynamics in pre-eclampsia compared with normal pregnancy during caesarean delivery | Q48697010 | ||
| Ambulatory blood pressure monitoring in pregnancy: what is normal? | Q48801473 | ||
| Rapid assessment of blood pressure in the obstetric day unit using Microlife MaM technology. | Q51019439 | ||
| Time poor: rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. | Q51156081 | ||
| An accurate automated blood pressure device for use in pregnancy and pre-eclampsia: the Microlife 3BTO-A. | Q51433914 | ||
| Bolus dose remifentanil for control of haemodynamic response to tracheal intubation during rapid sequence induction of anaesthesia. | Q51455291 | ||
| Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. | Q51598034 | ||
| Attenuation of the pressor response to tracheal intubation by magnesium sulphate with and without alfentanil in hypertensive proteinuric patients undergoing caesarean section | Q51702426 | ||
| Effects of alfentanil and fentanyl on induction of anaesthesia in patients with severe pregnancy-induced hypertension. | Q51726732 | ||
| An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial) | Q51752080 | ||
| First-trimester prediction of hypertensive disorders in pregnancy. | Q51775989 | ||
| Neuromuscular transmission studies in preeclamptic women receiving magnesium sulfate. | Q51779172 | ||
| Esmolol for control of increases in heart rate and blood pressure during tracheal intubation after thiopentone and succinylcholine. | Q51803750 | ||
| Cardiovascular alterations in severe pregnancy-induced hypertension: acute effects of intravenous magnesium sulfate. | Q51848621 | ||
| Can We Use the Omron T9P Automated Blood Pressure Monitor in Pregnancy? | Q53167732 | ||
| Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. | Q53254274 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Do hypertensive diseases of pregnancy disrupt neurocognitive development in offspring? | Q53666066 | ||
| Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial | Q57281371 | ||
| Hypertensive Diseases of Pregnancy and the Development of Behavioral Problems in Childhood and Adolescence: The Western Australian Pregnancy Cohort Study | Q57297227 | ||
| Outcomes at 2 Years of Age after Repeat Doses of Antenatal Corticosteroids | Q57581725 | ||
| Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study | Q58035948 | ||
| Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays | Q58623865 | ||
| A prospective study of the impact of automated dipstick urinalysis on the diagnosis of preeclampsia | Q35888426 | ||
| Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis | Q36050839 | ||
| Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial | Q36230294 | ||
| Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study | Q36428404 | ||
| Intensive care in obstetrics: an evidence-based review | Q36584100 | ||
| Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). | Q36756946 | ||
| The role of the anaesthetist in the management of the pre-eclamptic patient | Q36811015 | ||
| Can we predict recurrence of pre-eclampsia or gestational hypertension? | Q36851126 | ||
| A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma | Q36984261 | ||
| Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations | Q37020820 | ||
| Urinalysis vs urine protein-creatinine ratio to predict significant proteinuria in pregnancy | Q37345670 | ||
| Expectant management of severe preeclampsia remote from term: a structured systematic review. | Q37412528 | ||
| Pravastatin for the prevention of preeclampsia in high-risk pregnant women | Q37432893 | ||
| Predicting adverse outcomes in women with severe pre-eclampsia | Q37493258 | ||
| Accuracy of serum uric acid as a predictive test for maternal complications in pre-eclampsia: bivariate meta-analysis and decision analysis | Q37525274 | ||
| Use and safety of calcium channel blockers in obstetrics | Q37528481 | ||
| The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort | Q37579964 | ||
| Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach | Q37679676 | ||
| Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. | Q37776132 | ||
| Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies? | Q37823984 | ||
| Long-term complications of preeclampsia | Q37832329 | ||
| Transthoracic echocardiography in obstetric anaesthesia and obstetric critical illness | Q37840437 | ||
| Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. | Q37844756 | ||
| Postpartum evaluation and long term implications | Q37871188 | ||
| Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia | Q37935034 | ||
| Recommendations for the prevention of pregnancy-associated venous thromboembolism | Q37939191 | ||
| Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review | Q38012024 | ||
| The pathophysiology of preeclampsia involves altered levels of angiogenic factors promoted by hypoxia and autoantibody-mediated mechanisms | Q38014802 | ||
| Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review | Q38056216 | ||
| Cardiovascular disease risk in women with pre-eclampsia: systematic review and meta-analysis | Q38080492 | ||
| Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study | Q38093204 | ||
| Prophylaxis of thromboembolic events in patients with nephrotic syndrome | Q38101269 | ||
| Focused review: spinal anesthesia in severe preeclampsia | Q38122671 | ||
| ACOG Practice Bulletin No. 138: Inherited thrombophilias in pregnancy | Q38130442 | ||
| Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings? | Q38854457 | ||
| Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies | Q33930498 | ||
| The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community | Q33930523 | ||
| Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Associati | Q33983951 | ||
| ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. | Q33990220 | ||
| Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial | Q34021231 | ||
| Pre-eclampsia | Q34079933 | ||
| Management of mild chronic hypertension during pregnancy: a review | Q34091247 | ||
| Validation of the Omron M7 and Microlife 3BTO-A blood pressure measuring devices in preeclampsia | Q34165517 | ||
| Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. | Q34236115 | ||
| Management of pre-eclampsia: issues for anaesthetists | Q34316682 | ||
| Haemodynamic, invasive and echocardiographic monitoring in the hypertensive parturient | Q34322683 | ||
| Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension | Q34407777 | ||
| Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction | Q34500006 | ||
| Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. | Q34514153 | ||
| Vitamins C and E and the risks of preeclampsia and perinatal complications | Q34518082 | ||
| Major congenital malformations after first-trimester exposure to ACE inhibitors | Q34535854 | ||
| Pregnancy-induced hypertension, but not gestational diabetes mellitus, is a risk factor for venous thromboembolism in pregnancy | Q34580058 | ||
| Excretion of antihypertensive medication into human breast milk: a systematic review | Q34666718 | ||
| Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis | Q34708320 | ||
| Angiogenic factors and preeclampsia | Q34714082 | ||
| Eclampsia in the United Kingdom. | Q34722815 | ||
| Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort | Q34769574 | ||
| Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses | Q34897462 | ||
| Atenolol in essential hypertension during pregnancy | Q35170458 | ||
| Diagnosis and management of gestational hypertension and preeclampsia | Q35173115 | ||
| Maternal health-related quality of life after induction of labor or expectant monitoring in pregnancy complicated by intrauterine growth retardation beyond 36 weeks | Q35372982 | ||
| Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study | Q35384541 | ||
| Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis | Q35566921 | ||
| Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive blood pressure control | Q35671833 | ||
| Postpartum hypertension and nonsteroidal analgesia. | Q35674486 | ||
| Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women | Q35738094 | ||
| Fluid management in pre-eclampsia | Q35867638 | ||
| Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia | Q35871381 | ||
| P433 | issue | 5 | |
| P304 | page(s) | e1-29 | |
| P577 | publication date | 2015-09-28 | |
| P1433 | published in | Australian and New Zealand Journal of Obstetrics and Gynaecology | Q15764794 |
| P1476 | title | SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. | |
| P478 | volume | 55 |
| Q48341523 | A randomised controlled trial of consumption of dark chocolate in pregnancy to reduce pre-eclampsia: Difficulties in recruitment, allocation and adherence. |
| Q91555826 | Aspirin in the prevention of preeclampsia: the conundrum of how, who and when |
| Q92075024 | Assessing Knowledge Gaps of Women and Healthcare Providers Concerning Cardiovascular Risk After Hypertensive Disorders of Pregnancy-A Scoping Review |
| Q90734918 | Be Healthe for Your Heart: Protocol for a Pilot Randomized Controlled Trial Evaluating a Web-Based Behavioral Intervention to Improve the Cardiovascular Health of Women With a History of Preeclampsia |
| Q38377662 | Clinical Practice Guidelines for Hypertension: Evaluation of Quality Using the AGREE II Instrument |
| Q46581324 | DNA methylation profiles in preeclampsia and healthy control placentas |
| Q90641335 | Decreased ALCAM expression and promoter hypermethylation is associated with preeclampsia |
| Q61804588 | Developing management pathways for hypertensive disorders of pregnancy (HDP) in Indonesian primary care: a study protocol |
| Q90737682 | Diagnostic Performance of First Trimester Screening of Preeclampsia Based on Uterine Artery Pulsatility Index and Maternal Risk Factors in Routine Clinical Use |
| Q42377850 | Dwarfism and insulin resistance in male offspring caused by α1-adrenergic antagonism during pregnancy |
| Q48108593 | Epidural extension failure in obese women is comparable to that of non-obese women. |
| Q46309172 | Expectant management of severe preterm preeclampsia: a comparison of maternal and fetal indications for delivery. |
| Q89919134 | Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: A mixed method analysis |
| Q92594885 | Future risk of cardiovascular disease risk factors and events in women after a hypertensive disorder of pregnancy |
| Q39175116 | Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology |
| Q92482417 | Hypertensive Disorders of Pregnancy and Subsequent Cardiovascular Disease: Current National and International Guidelines and the Need for Future Research |
| Q61837360 | Hypertensive disorders in pregnancy and stillbirth rates: a facility-based study in China |
| Q64089847 | Increased expression and phosphorylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoforms in urinary exosomes in pre-eclampsia |
| Q99416564 | Midwives' knowledge of pre-eclampsia management: A scoping review |
| Q91712166 | Postpartum Interventions to Reduce Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: A Systematic Review |
| Q38930161 | Prediction and prevention of hypertensive disorders of pregnancy |
| Q90567542 | Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring |
| Q38779024 | Pregnancy Outcomes after Clinical Recovery from AKI. |
| Q59790990 | Risk factors for hypertensive disorders of pregnancy among mothers in Tigray region, Ethiopia: matched case-control study |
| Q92181089 | The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention |
| Q64090237 | The performance of pre-delivery serum concentrations of angiogenic factors in predicting postpartum antihypertensive drug therapy following abdominal delivery in severe preeclampsia and normotensive pregnancy |
| Q38829613 | Translational studies for exercise in high-risk pregnancy: Pre-eclampsia model |
Search more.